-
1.发明申请公开(公告)号：US20240392251A1
公开(公告)日：2024-11-28
申请号：US18692569
申请日：2021-10-26
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Jie HU , Cheng CHEN , Tao HUANG
IPC: C12N5/09
Abstract: A primary cell culture medium for culturing primary lung cancer epithelial cells, a culture method using the primary cell culture medium, and an application thereof in drug efficacy evaluation and screening. The culture medium contains an MST1/2 kinase inhibitor, a ROCK kinase inhibitor, a fibroblast growth factor, at least one additive selected from a B27 additive and an N2 additive, an epidermal growth factor, transferrin, gastrin, and a TGFβ type I receptor inhibitor.
-
公开(公告)号：US20240418703A1
公开(公告)日：2024-12-19
申请号：US18700796
申请日：2021-11-22
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Yuying HE , Tao HUANG , Cheng CHEN
Abstract: A culture medium for primary ovarian cancer cells, an in vitro culture method and an application thereof. The culture medium contains: an MST1/2 kinase inhibitor; a Rho kinase inhibitor, which is selected from at least one among Y27632, Fasudil and H-1152; an insulin-transferrin-selenium supplement; insulin; prostaglandin E2; an epidermal growth factor; gastrin; an insulin-like growth factor-1; cholera toxin; amphiregulin; N2; and B27. Compared with existing culture methods, the in vitro culture using said culture medium has higher amplification efficiency. Using the culture medium for the culturing of primary ovarian cancer cells may maintain the morphological structure and pathological features of primary tissues, and improve the success rate and survival rate of the cultured primary ovarian cancer cells.
-
公开(公告)号：US10781214B2
公开(公告)日：2020-09-22
申请号：US16066427
申请日：2016-12-27
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong Liu , Jing Liu , Xixiang Li , Aoli Wang , Hong Wu , Kailin Yu , Chen Hu , Wenchao Wang , Cheng Chen , Fengming Zou , Ziping Qi , Li Wang , Beilei Wang
IPC: C07D487/04 , A61K31/519 , A61P35/00
Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.
-
公开(公告)号：US20200010471A1
公开(公告)日：2020-01-09
申请号：US16306647
申请日：2017-06-05
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Jing LIU , Xixiang LI , Aoli WANG , Ziping QI , Hong WU , Jiaxin WU , Wenchao WANG , Chen HU , Cheng CHEN , Li WANG , Beilei WANG
IPC: C07D487/04 , A61P35/02
Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).
-
公开(公告)号：US20240344035A1
公开(公告)日：2024-10-17
申请号：US18685054
申请日：2021-08-31
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qing Song LIU , Yu Ying HE , Cheng CHEN , Tao HUANG , Tao REN , Wen Chao WANG , Li WANG
IPC: C12N5/09
CPC classification number: C12N5/0694 , C12N2500/32 , C12N2501/125 , C12N2501/22 , C12N2501/2303 , C12N2501/2306 , C12N2501/2307 , C12N2501/26 , C12N2503/02
Abstract: Provided are a culture medium and a culture method for human primary acute myeloid leukemia cells. The culture medium for human primary acute myeloid leukemia cells contains a glutamine additive, non-essential amino acids, human interleukin-6, human interleukin-7, human interleukin-3, recombinant human FLT3 Ligand, a recombinant human macrophage colony stimulating factor and a human stem cell factor. Acute myeloid leukemia cells can be cultured with higher amplification efficiency and longer in-vitro culture time by using the culture medium and culture method. Also provided are human primary acute myeloid leukemia cells cultured in vitro by using the culture medium, and the use thereof for curative effect evaluation and screening of drugs.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20230235283A1
公开(公告)日：2023-07-27
申请号：US17918971
申请日：2020-04-23
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Jie HU , Wenchao WANG , Cheng CHEN , Tao REN , Li WANG
CPC classification number: C12N5/0625 , C12N5/0693 , C12N2501/11 , C12N2500/25 , C12N2501/727 , C12N2501/12 , C12N2501/15 , C12N2503/02
Abstract: Provided are a primary cell culture medium that contains a combination of an MST1/2 kinase inhibitor and a ROCK kinase inhibitor and is used for culturing primary esophageal squamous cell carcinoma epithelial cells, and a culture method using the primay cell culture medium. In the culture method, the primary cell culture medium is used to culture primay cells on a culture vessel coated with an extracellular matrix glue, so that the primary cells prolilferate rapidly. A cell model obtained by using the primary cell culture medium and the primary cell culture method of the present invention can be used for the efficacy evaluation and screening of drugs.
-
7.发明申请公开(公告)号：US20230091960A1
公开(公告)日：2023-03-23
申请号：US17798640
申请日：2020-02-26
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Jie HU , Cheng CHEN , Wenchao WANG , Li WANG
Abstract: Provided are a culture medium and cultivation method of rapidly expanding primary cells of esophageal squamous carcinoma in vitro, and the use thereof in screening drugs. The culture medium comprises an initial culture medium selected from DMEM/F12, DMEM, F12, or RPMI-1640, a Rho protease inhibitor, an antibiotic, insulin, an N2 additive, insulin-like growth factor 1, a non-essential amino acid, and optionally, hydrocortisone, optionally, glutamine, and optionally, bovine pituitary extract.
-
8.发明公开公开(公告)号：US20240319169A1
公开(公告)日：2024-09-26
申请号：US18271773
申请日：2021-01-22
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Feiyang LIU , Xiaoyu LI , Husheng MEI , Wenchao WANG , Tao REN , Li WANG
CPC classification number: G01N33/5011 , C12N5/0693 , C12N2501/115 , C12N2501/119 , C12N2501/125 , C12N2501/135 , C12N2501/345 , C12N2533/54
Abstract: The present invention provides a cell culture medium for culturing primary gastrointestinal stromal tumor cells, comprising gastrin, N2, insulin, a receptor tyrosine kinase ligand, and a Rock kinase inhibitor. The present invention further provides a method for culturing gastrointestinal stromal tumor cells by using the cell culture medium, and an application and a method of an expanded cell population, which is obtained by using the method, in efficacy evaluation or screening.
-
公开(公告)号：US10975082B2
公开(公告)日：2021-04-13
申请号：US16306647
申请日：2017-06-05
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong Liu , Jing Liu , Xixiang Li , Aoli Wang , Ziping Qi , Hong Wu , Jiaxin Wu , Wenchao Wang , Chen Hu , Cheng Chen , Li Wang , Beilei Wang
IPC: C07D487/04 , A61P35/02 , A61K45/06
Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).
-
公开(公告)号：US20190084960A1
公开(公告)日：2019-03-21
申请号：US16089547
申请日：2017-03-28
Inventor： Qingsong LIU , Jing LIU , Qiang WANG , Beilei WANG , Feiyang LIU , Shuang QI , Ziping QI , Fengming ZOU , Cheng CHEN , Wenchao WANG , Chen HU , Xiaochuan LIU , Wei WANG , Aoli WANG , Li WANG , Zhenquan HU , Tao REN
IPC: C07D401/06 , A61K31/4545 , C07D211/44 , A61K31/445 , C07D413/06 , A61K31/454 , C07D401/14 , C07D409/14 , A61P35/00
Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.015 seconds)
